Companies

See how salaries can vary from company to company

Full-service mechanical maintenance and construction companies - Cullum has been the top name in service and construction organizations in the Southeast since 1972. Positively impacting and serving commercial and industrial industries is the company's goal, and operations are divided into two companies to continue to set the standard for customer service, quality, respect, innovation, and integrity. Cullum specializes in heating, air conditioning, plumbing, medical gas piping, and process piping projects. It also has extensive project experience with manufacturing facilities, laboratories, con... view company details

We specialize in providing HVAC, plumbing, and piping design and installation services across the state of California. Our core market segment includes educational facilities, multi-family and mixed-use high rises, and commercial/industrial projects. Creatively solving problems, delivering value, and exceeding expectations: this is the inspiration for everything we do at Iron Mechanical. We are a single source for the entire mechanical system of a building - from design, prefab, complete installation, all the way to preventative maintenance and service of the building. Our experienced team is ... view company details

Texas Mineral Resources Corp., an exploration stage mining company, acquires, explores, and develops mineral properties in the United States. It primarily holds interests in the Round Top rare earth-uranium-beryllium project covering 950 acres in Hudspeth County, Texas; and prospecting permits covering 9,345 acres adjacent to the Round Top project. The company was formerly known as Texas Rare Earth Resources Corp. and changed its name to Texas Mineral Resources Corp. in March 2016. Texas Mineral Resources Corp. was incorporated in 1970 and is headquartered in Sierra Blanca, Texas. view company details

Uranium Energy Corp. engages in exploration, pre-extraction, extraction, and processing uranium and titanium concentrates in the United States, Canada, and Paraguay. It owns interests in the Palangana mine, Burke Hollow, Goliad, Longhorn, and Salvo projects located in Texas; Anderson, Workman Creek, and Los Cuatros projects situated in Arizona; Slick Rock project in Colorado; Diabase project located in Canada; and Yuty, Oviedo, and Alto Parana titanium projects in Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. Uranium ... view company details

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to devel... view company details

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood The... view company details

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for ... view company details

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatme... view company details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has comp... view company details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatm... view company details

Gold Resource Corporation explores for, develops, produces, and sells gold and silver in Mexico and the United States. It also explores for copper, lead, and zinc. The company's flagship property is the Aguila project comprising 18 mining concessions aggregating approximately 25,264 hectares located in the State of Oaxaca, Mexico. Gold Resource Corporation was founded in 1998 and is headquartered in Colorado Springs, Colorado. view company details

NioCorp Developments Ltd. engages in the exploration and development of mineral deposits in North America. It owns and develops the Elk Creek niobium/scandium/titanium project located in Southeastern Nebraska. The company was formerly known as Quantum Rare Earth Developments Corp. and changed its name to NioCorp Developments Ltd. in March 2013. NioCorp Developments Ltd. was incorporated in 1987 and is headquartered in Centennial, Colorado. view company details

Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates c... view company details

Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO). The Acute Care division primarily focuses on developing products for the hospital and other acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has completed two pivotal Phase III clinical efficacy trials, a double-blind placebo-controlled Phase III safety trial, and four Phase II clinical efficacy trials, as well as oth... view company details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including ... view company details

ARC Document Solutions, Inc., a reprographics company, provides document solutions worldwide. It offers managed print services, an onsite service that places, manages, and optimizes print and imaging equipment in customers' offices, job sites, and other facilities; construction document and information management services, which consists of professional services to manage and distribute documents and information primarily related to construction projects; and archive and information management services that combines software and professional services to facilitate the capture, management, acce... view company details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmace... view company details

Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and i... view company details

XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis sup... view company details

ENGlobal Corporation provides engineering and professional services primarily to the energy industry in the United States and internationally. The company operates through two segments, Engineering, Procurement and Construction Management (EPCM); and Automation. The EPCM segment offers services relating to the development, management, and execution of projects requiring professional engineering and related project management services primarily to the energy industry, which include conceptual studies, project definition, cost estimating, engineering design, environmental compliance, material pr... view company details